Last Updated : April 22, 2019
Details
FilesGeneric Name:
Pralatrexate
Project Status:
Complete
Therapeutic Area:
Peripheral T-Cell Lymphoma (PTCL)
Manufacturer:
Servier Canada Inc.
Brand Name:
Folotyn
Project Line:
Reimbursement Review
Project Number:
PC0138-000
NOC Status at Filing:
Pre NOC
Strength:
20 mg/1 mL & 40 mg/2 mL
Tumour Type:
Lymphoma
Indications:
Peripheral T-Cell Lymphoma (PTCL)
Funding Request:
for the treatment of patients with relapsed or refractory PTCL
Pre Noc Submission:
Yes
Sponsor:
Servier Canada Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Requested and Not Granted
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Clarification:
The timeline of the review was temporarily stopped, pending receipt of the additional information. The timeline of the review has resumed as the additional information has now been provided.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Clarification:
The timeline of the review was temporarily stopped, pending receipt of the additional information. The timeline of the review has resumed as the additional information has now been provided.
pERC Meeting:
Final Recommendation Issued:
Files
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Last Updated : April 22, 2019